Related Links Educational Materials About Clinical Trials Clinical Trials Questions to Ask Your Doctor Drug Information from MedlinePlus

Alternate Title
Basic Trial Information
Trial Description
     Purpose
     Eligibility
     Treatment/Intervention
Trial Contact Information
Registry Information

Alternate Title

Diagnostic Study of Melastatin Expression to Predict Risk of Developing Local Regional Metastases in Patients With Primary Stage I or II Melanoma

Basic Trial Information

Phase	Type	Status	Age	Sponsor	Protocol IDs
No phase specified	Diagnostic	Closed	18 and over	NCI	CALGB-500105 NCT00049010

Trial Description

Purpose:

Diagnostic procedures that analyze surgically-removed tumor tissue and lymph node samples may help doctors identify patients with melanoma who are at risk for developing metastatic cancer.

This clinical trial is studying tumor tissue and lymph node samples to see how well they work in predicting the development of metastatic cancer in patients with stage I or stage II melanoma.

Eligibility:

Eligibility criteria include the following:

• At least 18 years old
• Planning to undergo sentinel lymph node biopsy or lymph node dissection within 7 weeks
• For more information about the eligibility criteria for this trial, refer to the Health Professional version.

Final eligibility for a clinical trial is determined by the health professionals conducting the trial.

Treatment/Intervention:

Tissue from the primary tumor and lymph nodes will be analyzed. Patients will not receive results of testing and the results will not affect treatment. Patients will be evaluated every 4 months for 3.5 years.

Important:

For more details about this trial, refer to the Health Professional version of the trial summary.

If you are interested in participating in a clinical trial, contact your doctor for a referral or call a trial contact person listed below. You may see the same contact person listed at more than one site, however, if you call the number listed you can ask to speak to the study coordinator or person involved with the specific trial you are interested in. If you have questions about cancer or clinical trials, call the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). General information about clinical trials, including risks, benefits, and costs, can be found on NCI's Web site.

Trial Contact Information

Trial Lead Organizations

Cancer and Leukemia Group B

F. Stephen Hodi, MD, Protocol chair		Ph: 617-632-5053; 866-790-4500

Registry Information
Official Title		Prospective Study of Melastatin Expression in Predicting the Risk for Developing Local Regional Metastases of Primary Melanoma
Trial Start Date		2002-09-15
Registered in ClinicalTrials.gov		NCT00049010
Date Submitted to PDQ		2002-08-02
Information Last Verified		2006-03-15
NCI Grant/Contract Number		U10-CA31946

Back to Top